Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Stephen James Nicholls, Imre J. Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, Abraham Michael Lincoff, Darren K. McGuire, Debra Lee Miller, Michael Albrecht Nauck, Hiroshi Nishiyama, Steven E. Nissen, Naveed A. Sattar, Govinda J. Weerakkody, Russell J. Wiese, Bernard Zinman, Sophia Zoungas, Jan Basile, Melanie J Davies, Francesco Giorgino, Monika Kellerer, Linong Ji, Tamás T. Várkonyi, Venu Menon, Jonathan C. Broder, and 2 more
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1056/nejmoa2505928
- Published
- Dec 17, 2025
- Venue
- New England Journal of Medicine
- DOI
- 10.1056/nejmoa2505928
- PubMed
- 41406444
- Categories
- Diabetes Treatment and Management
- Provenance
- openalex